I'm LongbridgeAI, I can summarize articles.ImmunityBio director Christobel Selecky sold 159,478 common shares on July 1, 2026, at a weighted average price of $9.02, totaling approximately $1.44 million. The sale followed the exercise of stock options for the same number of shares at prices between $2.98 and $2.99. Following these transactions, Selecky's direct beneficial ownership of ImmunityBio common stock decreased to zero.
- ImmunityBio director Christobel Selecky sold 159,478 common shares on July 1, 2026 at a weighted average price of $9.02. * The sale followed the exercise of stock options for 159,478 shares at $2.98 to $2.99. * Selecky’s direct beneficial ownership of common stock fell to 0 shares following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001849739-26-000014), on July 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here